Close Menu
March 30, 2021
Sponsored by
Menarini Silicon Biosystems

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Genome Webinar

Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Director of the OncoSET Precision Medicine Program,
Robert Lurie Cancer Center, Northwestern University

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Dr. Massimo Cristofanilli, Associate Director of Translational Research and Precision Medicine at Robert Lurie Cancer Center, Northwestern University, will review the evidence, as well as clinical case studies demonstrating how CTCs can be utilized in clinical practice and clinical research studies in metastatic breast cancer. 

A prominent figure in the liquid biopsy field, Dr. Cristofanilli led a pivotal study demonstrating the prognostic value of CTC enumeration using the semiautomated CellSearch technology. CellSearch has been cleared by the US Food and Drug Administration for detecting and enumerating circulating tumor cells to help manage patients with metastatic breast, prostate, and colorectal cancers.

Dr. Cristofanilli will discuss future developments and applications of CTCs in oncology. The session will wrap up with a live Q&A with Dr. Cristofanilli.

Sponsored by
Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.